Postmarketing Surveillance: Biosimilars, First-In-Class Approvals Will Not Get Extra Scrutiny
Executive Summary
Revised document on best surveillance practices for US FDA staff deletes some product categories subject to more extensive monitoring. It also no longer recommends focusing on adverse events reported in a specific population.